html On the evening of April 5, Aier Ophthalmology released its 2016 annual report and 2017 first quarter report preview. According to the announcement, the company achieved operating income of approximately 4 billion yuan in 2016, an increase of 26.37% over the same period last year; and a net profit attributable to shareholders of listed companies of 557 million yuan, an increase of 30.24% over the same period last year. At the same time, the company expects to achieve a net profit attributable to shareholders of listed companies of 150 million to 160 million yuan in the first quarter of 2017, a year-on-year increase of 30% to 35%. The annual report of shows that the growth momentum of Aier Ophthalmology’s three main businesses continues unabated. Among them, refractive surgery achieved revenue of 1.141 billion yuan, a year-on-year increase of 35.94%, cataract surgery achieved revenue of 981 million yuan, a year-on-year increase of 22.36%, and optometry services achieved revenue of 872 million yuan, a year-on-year increase of 36.67%.
In 2016, Aier Ophthalmology achieved 3.71 million outpatient visits, a year-on-year increase of 15.24%, and performed 370,000 surgeries, a year-on-year increase of 16.74%. According to this estimate, the unit price per customer of Aier Eye Hospital in 2016 increased by about 10% year-on-year. Analysis by Haitong Securities believes that the main reason for the increase in unit price is the upgrading of surgical consumption. For example, the proportion of full-femtosecond patients in refractive surgery has gradually increased. With the improvement, the proportion of high-end lenses in cataract surgery has gradually increased, and the proportion of orthokeratology lenses in optometry services has gradually increased. However, Aier Ophthalmology was affected to a certain extent by the "cataract incident" last year, but judging from its performance, the impact of this incident on its overall business has gradually weakened.
At present, Aier Eye Hospital continues to accelerate the vertical layout of prefecture-level and county-level medical networks in various provinces through the "self-construction + industrial M&A fund" model, and at the same time explores the optometry development model and community eye health service model horizontally in the city. On the one hand, the company has built Zhengzhou Aier Eye Hospital , Luzhou Aier Eye Hospital and Ningxiang Aier Optometry Clinic with its own funds; on the other hand, the company has reserved a large number of high-quality M&A targets through industrial merger and acquisition funds. Last year, AIER Ophthalmology participated in the establishment of 6 companies including Nanjing AIER Anxing Eye Medical Industry Investment Fund and Ningbo Honghui Equity Investment M&A Fund.
Health Point learned that currently has more than 160 hospitals under its own and M&A funds owned by Aier Eye Hospital, including comprehensive layout in provincial capitals. plans to open in 200 prefecture-level municipal hospitals by the end of 2017. Judging from the income distribution of the company's top ten hospitals that have developed relatively maturely, Wuhan Aier has an income of more than 300 million yuan in 2016, Shenyang Aier and Changsha Aier have an income of 200 to 300 million yuan. The top three hospitals are all second-tier city hospitals, and their growth rates have remained at 10% to 20% in recent years due to consumption upgrades. In addition, the revenue of some prefecture-level and municipal hospitals in Aier Ophthalmology, such as Hengyang Aier, has exceeded 100 million yuan.
At present, Aier Ophthalmology has formed a hierarchical chain model of "central city hospital - provincial capital hospital - prefecture-level hospital - county-level hospital ", and there are many mature hospitals gradually occupying the local market in terms of outpatient volume, operation volume, operating income, etc. largest market share. Some analysts believe that single hospitals are prone to ceilings in treatment services, so they must choose a replicable model. The chain model of Aier Eye Hospital is simple, standardized, and professional, and is highly replicable. The efficiency of scale-up replication continues to improve.
In addition, Aier Ophthalmology is also actively deploying mobile medical care. At present, Hunan Jishi Internet Technology Co., Ltd., which it invests in, has deployed a number of community eye-care e-stations in Changsha, Tianjin, Chengdu and other places. Through the collaboration of online cloud service platforms and offline eye-care e-stations, it has created online and offline A combined community eye health service model; the wearable device product "Cloud Clip" launched by Hangzhou Mirror Mirror Technology Co., Ltd. in which it invested has been launched; it has deployed domestic telemedicine by increasing capital in Taiwan Jinhong Technology Co., Ltd.
-end-
